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depression using the Montgomery-Åsberg Depression Rating
Scale (MADRS). Baseline characteristics were compared to
reveal potential confounders, and adjusted mean HRQL change
from baseline were compared using analysis of covariance.
RESULTS: A total of 288 RCT patients and 244 patients from
the observational study were compared. At baseline, patients
from the observational study were statistically signiﬁcantly
younger (44.0 ± 14.5 vs. 48.0 ± 14.0, p = 0.002) and more
severely impaired (MADRS: 33.0 ± 7.4 vs. 28.9 ± 5.2, p < 0.001)
than RCT patients. Baseline EuroQoL scores were signiﬁcantly
higher for RCT patients (0.50 ± 0.28 vs. 0.30 ± 0.25, p < 0.001),
indicating a better HRQL, while QLDS scores were not signiﬁ-
cantly different (18.0 ± 4.4 vs. 17.9 ± 5.4, p = 0.69). Both
adjusted mean HRQL change from baseline scores were signiﬁ-
cantly lower for RCT patients than for patients from the obser-
vational study: -5.8 ± 0.3 vs. -7.6 ± 0.3, p < 0.001 and 0.31 ±
0.11 vs. 0.38 ± 0.09, p < 0.05 for QLDS and EuroQoL, respec-
tively. CONCLUSIONS: Improvement in HRQL scores during
acute treatment of MDD seems to indicate that their results may
be underestimated in RCT’s.
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OBJECTIVES: Estimate incidence, prevalence and pattern of
care in sickness fund insured patients with ADHD symptoms in
The Netherlands. METHODS: Claims data on approximately 6
million sickness fund insured persons during 1999–2001.
Patients on (chronic) methylphenidate (n@13,000) treatment
were assumed having ADHD symptoms. Both incident and
prevalent patients were identiﬁed and analysed. RESULTS:
Overall, ADHD prevalence and incidence was 0.24% and 0.07%
respectively. The overall male/female ADHD prevalence ratio
(%) was 0.43 :0.08. The highest prevalence and incidence ﬁgures
were seen in the 10–14 year age category with 1.8% and 0.35%
respectively. In 2000 the mean number of days of therapy were
165 days (75th percentile; 240). Average number of prescriptions
for prevalent and incident patients were 6 and 4. Of the
methylphenidate prescriptions 46% belong to the GP, 9% to a
paediatrician and 6% to a psychiatrist. For both the family
doctor and specialist together this was 23%. In children/adoles-
cents and adults (>20 years) the GP prescribes 42% and 43%
respectively. For paediatricians and psychiatrist these ﬁgures
were 14% and 4%. The most prescribed co-medication (ATC2)
for children, adolescents a) and adults b) were; J01 a) 8.8%, b)
3.5%; N02 a) 2.7%, b) 3.9%; N05 a) 11.6%, b) 26.4%; N06
a) 3.4%, b) 17.3%; R03 a) 8.4% b) 3.8%; R06 a) 4.8%, b) 2%
(ﬁgures as an average 1999–2001). Twelve percent (12%) of chil-
dren aged 10–14 received an RO3 preparation. CONCLU-
SIONS: ADHD is a common disorder. Highest prevalence was
seen in the 10–14 year age category. In general, ADHD patients
are slightly compliant with methylphenidate drug treatment.
Overall the family doctor plays an important role in the treat-
ment of ADHD. Both psycholeptics and psychoanaleptica are
commonly used as (co-) medications, especially in adults. A high
co-morbidity or complex diagnosis could be an explanation.
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OBJECTIVES: To present preliminary baseline data on the treat-
ment of Attention-Deﬁcit/Hyperactivity Disorder (ADHD)
symptoms and on observed co-morbid problems in German
patients enrolled in the ADORE study (Attention Deﬁcit Hyper-
activity Observational Research in Europe). METHODS:
ADORE is an ongoing 24 month, pan-European, prospective,
observational study to describe the relationship between treat-
ment regimen prescribed and quality of life in ADHD. Only
patients not formally diagnosed with ADHD previously were
included. RESULTS: A total of 392 patients with a mean age of
8.7 (SD 2.1) years with inattentive/impulsive/hyperactive symp-
toms were enrolled, of which 300 (77%) were male. ADHD
symptoms were ﬁrst observed at a mean age of 5.0 (SD 2.5)
years, while treatment was ﬁrst sought at a mean age of 7.1 (SD
2.3) years. A total of 384 subjects (98%) were formally diag-
nosed with ADHD at baseline for the ﬁrst time—the vast major-
ity according to DSM IV or ICD 10 criteria. The mean baseline
score on the ADHD Rating Scale-IV was 33.0 (SD 9.0). The
mean Clinical Global Impression-Severity score was 4.4 (SD 0.9).
The most commonly reported comorbid psychiatric symptoms
were related to: oppositional deﬁant (N = 271 (69%)) and
conduct (N = 240 (61%)) disorders, anxiety (N = 108 (28%))
and learning disorders (N = 243 (62%)). Investigators prescribed
pharmacotherapy in 78 cases (20%), some form of psychother-
apy in 66 cases (17%), and a combination of pharmacotherapy
and psychotherapy in 84 cases (21%). Short-acting
methylpenidate was prescribed for 159 (95%) out of 162
patients (41%) receiving pharmacotherapy. Psychoeducation/
counselling was prescribed for 156 (40%) and cognitive behav-
ior therapy for 44 (28%) of the patients/families. CONCLU-
SIONS: Baseline data showed: 1) an average gap of two years
between ﬁrst symptoms and seeking treatment; 2) frequent
comorbid problems; and 3) prescription of some form of treat-
ment in approximately two thirds of patients.
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OBJECTIVES: To examine the effects of initial ziprasidone dose
on discontinuation rates, using PharMetrics integrated medical
and pharmacy claims data. METHODS: Patients ≥18 years with
a diagnosis of schizophrenia and a ziprasidone claim between
March, 2001 and February, 2003, and continuously enrolled for
≥6 months before and ≥3 months after initiation of ziprasidone,
were stratiﬁed by initial daily dose (≥40 to <80mg [Low] vs. ≥80
to <120mg [Medium] vs. 120–160mg [High]). The 6-month risk
of discontinuation was examined using Cox proportional
hazards models controlling for gender, psychiatric comorbidities,
and pre-ziprasidone utilization of antipsychotics (atypical, con-
